Sidorenko B A, Preobrazhenskiĭ D V, Batyraliev T A, Belenkov Iu N
Kardiologiia. 2011;51(1):100-8.
The review is devoted to different aspects of pulmonary arterial hypertension (PAH); new classification of PAH is published in 2010. There are idiopathic PAH and PAH associated with other diseases. Current guidelines recommend to treat PAH only after the verification of diagnosis with right heart catheterization and acute tests with vasodilators. Patients-reactors should be treated with calcium antagonists. The following drugs related to one of three categories should be used in PAH: (1) prostanoids (epoprostenol, iloprost et al.); (2) blockers of endothelin receptors (bosentan, ambrisentan, sitaxsentan); (3) phosphodiesterase 5 type inhibitors (sildenafil, tadalafil et al.) In majority of cases the combined treatment is used, usually the combination of bosentan and sildenafil is used.
这篇综述致力于肺动脉高压（PAH）的不同方面；2010年发布了PAH的新分类。有特发性PAH以及与其他疾病相关的PAH。当前指南建议仅在通过右心导管检查核实诊断并进行血管扩张剂急性试验后才治疗PAH。有反应的患者应使用钙拮抗剂治疗。PAH应使用以下与三类之一相关的药物：（1）前列环素类（依前列醇、伊洛前列素等）；（2）内皮素受体阻滞剂（波生坦、安立生坦、西他生坦）；（3）5型磷酸二酯酶抑制剂（西地那非、他达拉非等）。在大多数情况下采用联合治疗，通常使用波生坦和西地那非的联合。
